Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine by Tajti, János et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS 14:(4) pp. 540-553. (2015)
 
Role of Pituitary Adenylate-Cyclase-Activating Polypeptide in nociception and migraine
Running title: PACAP: nociception and migraine
János Tajti1, Bernadett Tuka2, Bálint Botz3,4, Zsuzsanna Helyes3,4, László Vécsei*1, 2
1 Department of Neurology, Faculty of Medicine, University of Szeged, Szeged, Hungary
2 MTA – SZTE Neuroscience Research Group, Szeged, Hungary
3 Department of Pharmacology and Pharmacotherapy, University of Pécs, Pécs, Hungary
4Szentágothai Research Centre, University of Pécs, Pécs, Hungary
*Corresponding author: 
László Vécsei, MD, DSc
Director, Department of Neurology
Faculty of Medicine, University of Szeged 
Albert Szent-Györgyi Clinical Centre 
Semmelweis u. 6.
H-6725 Szeged, Hungary
Phone: +36 62 545348
Fax: +36 62 545597
E-mail: vecsei  .laszlo@med.u-szeged.hu
Abstract
Pituitary  Adenylate  Cyclase-Activating  Polypeptide  (PACAP)  and  its  receptors  are  widely
distributed  at  different  levels  of  the  pain-processing  pathway.  Its  action  at  the  peripheral
sensory nerve  terminals  has  been  found  to  be  divergent;  it  can  exert  both  pro-  and  anti-
nociceptive  effects,  depending  on  the  mode  of  administration  (local  or  systemic)  and  the
mechanism of the pain process (acute or chronic, inflammatory or neuropathic). In the central
nervous  system  it  exerts  mainly  neuronal  excitation,  leading  to  increased  nociceptive
signalling.    Since  the  clinical  data  strongly  suggest  the  involvement  of  PACAP in  the
pathophysiology of migraine, special emphasis is placed on examinations of its role and the
mechanisms   of   activation   of   the   trigeminovascular   system   (TS).   The   intravenous
administration  of  PACAP to  migraineurs  induces  migraine-like  headache  and  extracranial
arterial dilatation. Furthermore, an increased PACAP concentration has been detected in the
peripheral blood of patients during a migraine attack. Animal experiments have also revealed
that PACAP elicits peripheral and central sensitization of the neuronal elements of the TS and
evokes meningeal vasodilatation. This review summarizes data relating to the expression of
PACAP and its receptors, and the main effects and mechanisms in the nociceptive pathways,
with special emphasis on migraine. It is clear that PACAP plays an excitatory role in migraine,
but its target and signalling pathways have not yet been elucidated due to the lack of non-
peptide,  selective  agonists  and  antagonists.   Identification  of   its  up-  and  downstream
regulations and receptorial molecular mechanisms might open up future perspectives for the
development of novel analgesic drugs.
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Introduction
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is a member of the Vasoactive
Intestinal Polypeptide (VIP)/secretin/glucagon neuropeptide superfamily and is considered to
be a “brain-gut peptide” due to its  widespread expression and divergent  biological  effects
through the peripheral  (PNS) and central  (CNS) nervous systems [1;  2].  Since PACAP is
expressed at several levels of the pain transmission pathways, recent research activities have
focused extensively on its roles in nociception. Despite the considerable interest  and huge
amount of data relating to this topic [2-5], the overall impact of PACAP in pain is still
debated. There are many reasons for the contradictory results, as the effects of PACAP
depend on both  the underlying mechanisms and the site  of  action.  Delineating  its  role  in
nociception  and  pain  perception  has  proved  to  be  challenging  because  of  its  numerous
downstream targets, and also the considerable overlap of its receptorial pathways with those
of VIP, to which it is closely related.
Among  the  several  pain  conditions,  special  emphasis  has  been  placed  on  migraine  in
consequence of the important clinical findings. Migraine is a primary headache disorder with
a high socio-economic and personal impact, affecting almost 16% of the adult population [6].
It was ranked by a WHO report as the 19th cause of disability worldwide [6-8], but the precise
pathophysiological mechanisms are still unclear [9]. Several hypotheses have been proposed
to explain the initiation of migraine pain. Although the predisposition to its development is
presumably genetically determined, certain environmental factors (alcohol, alimentary factors,
stress,  hormonal  changes,  etc.)  can  trigger  the  headache.  The  factors  assumed  in  the
background include neurovascular alterations, sensory neuropeptide release and consequent
neurogenic inflammation, plasma protein extravasation, peripheral and central sensitization,
cortical spreading depression (CSD), a brain energy deficit and lesions in the white matter, as
separately or  simultaneously occurring  phenomena.  Since  the  1990s,  the  central  theme of
migraine research has been the trigeminovascular theory [10]. The trigeminovascular system
(TS) provides an important link between the vascular and neuronal elements, because this is
the major afferent pain pathway between the cranial vessels and the brainstem [11]. The TS
consists of the pseudounipolar primary sensory neurons whose cell bodies are located in the
trigeminal ganglia (TRIG), their terminals innervating the cranial vessels, the supratentorial
mater,  the  dural  vasculature  and  the  pial  arteries and  central  endings  projecting  to  the
trigeminal nucleus caudalis (TNC). The third-order neurons are located in the thalamus. The
descending pathways from the monoaminergic nuclei  (the nuclei  raphe,  the periaqueductal
grey matter (PAG) and the locus coeruleus (LC)), which are considered to be migraine
generators, control the central components of the TS.  During activation of the TS, peripheral
and central sensitization develops [9; 11-14]. The consequences of peripheral sensitization are
the throbbing nature and worsening of the headache pain due to intracranial hypersensitivity
in  response  to  physical  activity  [15].  Cephalic  and extracephalic  cutaneous  allodynia  and
extracranial tenderness are the results of the central sensitization [15; 16].
One of the leading current hypotheses is based on the activation of the TS, which consists in
vascular alterations in the dura mater and the cerebral cortex, and also neuronal sensitization
[9]. Human and preclinical experimental studies have revealed that PACAP has a crucial role
in  the  activation  of  the  TS  [17].  Intravenous  PACAP  administration  causes  immediate
headache in healthy volunteers, and delayed migraine-like strong pain in migraineurs without
aura, and additionally induces pronounced dilatations of the extracranial arteries [18-20]. In
spontaneous  migraine  attacks,  increased  concentrations  of  PACAP  are  observed  in  the
peripheral blood relative to the headache-free period [21]. Electrical and chemical stimulation
of the rat TS elevates the PACAP concentrations in the extracranial bloodflow and the TNC
[22].   In a model of chemical TS activation, the light aversive behaviour (mimicking the
symptom of photophobia), meningeal vasodilatation and c-fos activation in the TRIG and
TNC are significantly decreased in PACAP-deficient mice [23].
Distribution of PACAP and its receptors in the CNS and PNS
PACAP was discovered thanks to its ability to increase the adenylate cyclase activity in rat
pituitary cells, and it was first isolated from the ovine hypothalamus in 1989 [24]. The
PACAP gene (ADCYAP1) is localized on the short arm of chromosome 18 [25]. The peptide
exists in two biologically active amidated forms, containing 38 and 27 amino acids, PACAP-
38 and PACAP-27 [2; 26]; the longer one is the predominant form in most mammalian tissues,
accounting for 90% of the total PACAP content. Both forms are rapidly metabolized and
theirs plasma elimination half-lives are less than 5 min [27].
It was established relatively early that PACAP is expressed in diverse regions of the CNS and
PNS. Pronounced PACAP expression was demonstrated in the superficial layer of the spinal
dorsal  and  ventral  horns,  in  the  dorsal  root  ganglia  (DRG)  and  the  TRIG,  and  also  in
peripheral nerve fibres [28-30]. Strong PACAP immunoreactivity was detected in the dorsal
horn of  the human spinal  cord and the PAG [31].  Low to moderate  amounts  of  PACAP-
immunoreactive (-ir) fibres were observed in the C
1 
and C
2 
levels of Rexed’s laminae I and II
and in the tract of Lissauer [32; 33]. A closer inspection of the PACAP-38 immunoreactivity
within the  spinal  cord  revealed  that  not  only  the  dorsal  horn,  but  also  the  lateral  horn,
numerous regions of  the medulla  and DRG demonstrate  a  considerable expression of this
peptide [34]. In the human TRIG, 20% of the neurons show PACAP immunoreactivity [35],
similarly as in the rat TRIG [28; 29]. Double staining revealed that approximately 68% of the
nociceptin-positive  cells  contained  PACAP [36].  In  the  human  DRG,  the  majority  of the
ganglion cells (59%) were also PACAP-ir [33]. In situ hybridization in the rat DRG indicated
approximately 10% PACAP-containing neurons [29], while about 30-45% of the lumbar
DRG  neurons  were  PACAP-ir  [37;  38].  PACAP is  also  expressed  in  capsaicin-sensitive
primary  sensory  neurons  [39];  pretreatment  with  capsaicin  reduces  the  PACAP
immunoreactivity [28].  Furthermore,  a  noteworthy co-localization  has  been observed with
calcitonin gene-related peptide (CGRP), VIP and substance P (SP) in the porcine sensory
distal  ganglion  of  the  vagus  (nodose  ganglion),  implicating  its  involvement  in  vagal
nociceptive transmission [40]. Only very few PACAP-ir fibres have been detected in the rat
dura mater, showing co-expression with CGRP [41]. In the human skin, PACAP is localized
in the dermal nerves in connection with the sweat glands [42], mast cells and hair follicles
[43; 44].
As concerns the brain, in human cerebral cortical areas the highest concentrations of PACAP-
38   have   been   detected   in   the   cingulate,   insular,   temporal,   parahippocampal   and
somatosensory cortex, the LC, the TNC and the dorsal vagal complex [31]. About 40% of the
human LC neurons are PACAP-ir, while there is little expression in the PAG [45], and only
moderate expression in the TNC [32] (Fig. 1, Table 2).
Besides  the  CNS,  PACAP occurs  widely  in  a  broad range  of  peripheral  organs  [46]  and
endocrine [47; 48] and exocrine glands [31; 49; 50]. In the PNS, it was first described in the
parasympathetic  system  [24]  and  later  in  sensory  neurons  [28;  35].  It  functions  as  a
pleiotropic peptide [51; 52]: it is a hypophysiotrophic hormone [53], a neurotransmitter and a
neuromodulator  in  the  CNS [54]  that  exerts  neuroprotective  [55],  anti-apoptotic  [56]  and
differentiation-promoting  effects  [57;  58].  Furthermore,  it  serves  important  regulatory and
protective roles in the gastrointestinal [59], cardiovascular [60-62], reproductive [63; 64] and
respiratory systems [65].
PAC
1
, VPAC
1 
and VPAC
2 
receptors
The effects of PACAP are mediated through three receptors: VPAC
1  
(previously designated
the VIP, VIP1 or PACAP type II receptor), VPAC
2 
(known as the VIP2 or PACAP type III
receptor) and PAC
1  
(formerly known as the PACAP type I receptor). The latter displays a
1000-fold higher specificity for both forms of PACAP than for VIP [66; 67]. The binding of
PACAP to  its  receptors  induces  two  main  signal  transduction  pathways.  Through  Gs-  or
Gq/11-protein  activation,  a  number  of  kinases  exert  a  variety  of  physiological  and
pathophysiological effects [2; 66].
In the rodent and human brain, pronounced PACAP-specific binding has been identified in 
the olfactory bulb, the cerebral cortex, the septum and amygdala, the hippocampus, the 
thalamus, the hypothalamus, the substantia nigra, the cerebellum and the area postrema [2]. 
High and moderate PACAP binding relating to migraine has also been found in the raphe nuclei,
the LC, the nuclei of the trigeminal complex and the spinal trigeminal nucleus [2]. In the rat, the
VPAC
1  
and VPAC
2  
receptors occur mainly in the olfactory bulb, the cerebral cortex, the 
dentate gyrus, the pineal gland and the thalamus. Although PACAP and VIP binding sites have 
been demonstrated in certain regions of the human brain (the cortex, basal ganglia, 
hypothalamus, cerebellum and brainstem), PACAP has a greater affinity than VIP for these sites.
All three receptors are present both in neurons and in glial cells [2]. In the second- order 
neurons, the presence of VPAC
1  
and PAC
1  
receptors has been shown [68], while VPAC
1
, 
VPAC
2  
and PAC
1  
receptors have been located in the rat middle cerebral artery by 
immunohistochemistry and Western blotting [69]. Multiple variants of the PAC
1  
receptor 
have been found besides the VPAC
2  
receptors in the rat middle meningeal arteries [70]. In 
another human study the VPAC
1  
receptors have been detected in the meningeal arteries, as
relevant  factors  of  migraine  [71].  Furthermore,   VPAC
2   
receptor  expression  has  been
identified in human mast cells [72]. All three receptors are also present in the spinal dorsal
horn. VPAC
1 
is the most widely expressed (laminae II-IV), whereas the VPAC
2 
expression is
lower in these regions. PAC
1 
mRNA is expressed in both the ventral and dorsal horns and in
the DRG, but its expression is unaltered following unilateral sciatic nerve transection [37].
VPAC
2 
and several PAC
1 
receptor splice variants have been found in small-diameter neurons
in the rat TRIG [73]. VPAC
1
, VPAC
2  
and PAC
1  
receptor mRNAs are present in the human
TRIG [74], while PAC
1 
receptors are expressed in the primary sensory neurons and Schwann
cells of the monkey TRIG [75] (Fig. 1, Table 2).
Early mechanistic insight: PACAP expression is influenced by peripheral nerve injury 
Sciatic nerve transection increases the number of PACAP-ir neurons in the respective DRGs, 
in contrast with the expression and mRNA levels of CGRP or other neurotransmitters [37; 38;
76]. An elevated PACAP expression has also been observed in a population of large ventral
horn motoneurons following sciatic  nerve transection,  suggesting its  role  in  motor  neuron
regeneration  and  repair  [30].  On  the  basis  of  these  results,  PACAP was  proposed  as  an
important protective factor in the CNS that is upregulated following nerve injury [77]. Since
then, numerous studies have confirmed that PACAP is an endogenous neuroprotective factor
in a variety of conditions [78-81].
PACAP plays a key role in peripheral nociceptive signalling
PACAP-38 is released from the stimulated peripheral endings of capsaicin-sensitive sensory 
neurons and diminishes the release of both pro-inflammatory/pronociceptive (SP and CGRP) 
and anti-inflammatory peptides (somatostatin) [82]. The PACAP immunoreactivity increased in 
the systemic circulation in response to systemic, but local excitation of cutaneous afferents by 
the ultrapotent capsaicin analogue resiniferatoxin (RTX). Intraperitoneal PACAP-38 ameliorated
capsaicin/RTX-induced purely neurogenic plasma protein extravasation in the paw skin, and 
also carrageenan-induced mixed neurogenic/non-neurogenic hindlimb edema. These results 
suggest that PACAP released from the capsaicin-sensitive sensory terminals into the circulation 
reduces inflammatory reactions and pro-inflammatory mediator production [83] (Table 1). 
Later results revealed that intraplantar PACAP-38 was able to inhibit carrageenan-induced 
mechanical hyperalgesia, noxious heat-induced thermal hyperalgesia, and both the 
immediate and tonic phase of the nociceptive responses in the formalin test in rats, without 
influencing the baseline mechano- or thermonociceptive thresholds. In mice,
PACAP-38 ameliorated acetic acid-induced visceral pain, but did not influence neuropathic
mechanical hyperalgesia in the partial sciatic nerve ligation model. These effects of PACAP-
38 were blocked by pretreatment with VPAC
1/2
, but not by the PAC1 receptor antagonist [84].
PACAP was also linked to inflammatory pain, as the number of PACAP mRNA-expressing
sensory neurons was significantly upregulated in the rat L5 DRG early after an intraplantar
challenge with complete Freund’s adjuvant, but not in the later phase of the inflammation [85].
Intravitreal   injection   of   PACAP-27   or   -38   elicited   an   inflammation-like   response
characterized by conjunctival hyperaemia, swelling and flare in rabbits. A topical challenge
by other  noxious  stimulants  (e.g.  formaldehyde or  endotoxin)  resulted  in  elevated  PACAP
immunoreactivity   in  the  aqueous   humour  [86].  PACAP-containing  nerve  fibres   were
previosuly  identified  in  several  parts  of  the  rat  temporomandibular  joint,  including  those
innervating  the  synovial  membrane,  the  joint  capsule,  and  the  articular  disc  [87].  In  the
adjuvant-induced paw inflammation model of the rat, an increased expression was shown in
tyrosine kinase A-expressing small/medium-sized DRG neurons. The systemic administration
of anti-nerve growth factor (NGF) resulted in diminished PACAP expression in responsive
neuronal  populations.  Moreover,  higher  doses  of  anti-NGF  were  capable  of  decreasing
PACAP expression in the non-inflamed DRGs. NGF a known mediator of inflammatory pain,
is  therefore  likely  to  be  an  endogenous  positive  modulator  of PACAP  besides  other
pronociceptive peptides such as SP [88].
Local  injection  of PACAP-38  increased  rotation-induced  afferent  firing in  the  acute
carrageenan/kaolin-induced synovitis model of the rat, which suggests its role in peripheral
mechanical  sensitization  of  the  knee  joint  primary  afferents,  and  the  induction  of  joint
mechanosensitivity [84], similarly to VIP [89]. However, it remains an open question as to
whether  this  is  due to  the  direct  action  of  PACAP, or  the  effect  of  secondary sensitizing
mediators released, for instance, during mast cell degranulation.
Only minimal information is available concerning the effect of PACAP on pain perception in
humans.  In  healthy  volunteers,  intradermal  injection  of  PACAP-38  (200  pmol)  into  the
forearm induces cutaneous pain, similarly to VIP. VIP evokes a more pronounced skin blood
flow increase and flare than does PACAP-38. These results suggest that the acute peripheral
pronociceptive effect of PACAP-38 is not PAC
1, 
but rather VPAC
1
/
2
-receptor-mediated [44]
(Table 1). The observed hyperaemia and flare together with the pain mirror the classical
picture of neurogenic inflammation (Fig. 2).
PACAP, as a regulator of central pain transmission
It was observed relatively early that capsaicin treatment induces PACAP release from the C-
fibres of the spinal cord, suggesting its potential modulator role in nociception [90]. In acute
models  of  somatic  or  visceral  inflammatory  pain  conditions,  PACAP  decreases  pain
transmission.  Intrathecal  (i.t.)  injections  of  both  PACAP-27  and  38,  even  in  small
concentrations, produce a long-lasting suppression of the C-fibre-evoked flexor reflex, though
PACAP-38 was found to be less potent [91]. In the formalin test of the rat, both forms of
PACAP elicited an antinociceptive effect in a high dose (~15.5 nmol i.t.), but also induced a
motor impairment [4; 92]. Later data with lower doses of PACAP-27 (0.06-5 pmol) in the
formalin  test  also  revealed  a  clear  antinociceptive  effect,  but  without  observable  motor
incapacitation [93]. PACAP-27 (3 pmol–3 nmol i.t.) elicited a dose-dependent facilitation of
the spinal nociceptive flexor reflex, with no inhibitory effect at any of the applied doses that
cause an excitatory effect in the spinal cord [94].
PACAP-38 administration in low doses (10–100 pmol i.t.) decreased noxious heat-induced
tail-flick latency,  whereas higher doses (0.2-2 nmol) triggered pain behaviour immediately
following  injection  [95].  Later  investigations  confirmed  the  presence  of an  aversive
behavioural response following i.t PACAP-38, which became pronounced above a dosage of
50 pmol. Immediately upon administration (30–90 s), a brief increase in tail-flick latency was
observed, followed by a long-lasting algesia. The PACAP-38-induced aversive behaviour had
a relatively slow onset, but long duration, in contrast with  SP, for example [96]. Other
researchers have observed that PACAP-38 (0.05-0.5 µg i.t.) diminishes the paw-withdrawal
latencies induced by thermal stimulation in a dose-dependent manner, while it augments the
aversive behaviour (licking and biting) induced by i.t. NMDA. Pretreatment with either the
PAC
1 
receptor antagonist PACAP6-38 or PACAP-antiserum did not influence the immediate
nociceptive response in the formalin test, but diminished the late-phase algesia. PACAP-38
also potentiated NMDA receptor-mediated currents in the spinal dorsal horn neurons, and it
was   therefore   suggested   that   PACAP   might   increase   the   NMDA   receptor-mediated
nociceptive responses by the sensitization of dorsal horn neurons [97].
Recent results suggest that PACAP is a key player in central pain processing by modifying a
variety of neurochemical mechanisms through divergent pathways. There is limited evidence
that PACAP is able to influence the central opioidergic tone. PAC
1
-receptor activation by
PACAP-38 inhibited, whereas antagonism by PACAP6-38 increased dynorphin 1-17 (Dyn)
release in the rat spinal cord. This implies that PACAP inhibits Dyn release in the CNS via
PAC
1   
activation,  and  antagonism  of  this  effect  results  in  antinociceptive  action.  The
frequnetly observed  pronociceptive  central  effect  of PACAP is therefore  at  least  partially
attributed to the tonic inhibition of opioid release by PAC
1 
activation [98]. This points to the
possibility of a bidirectional connection between opioid mediators and transmitters released
from the primary afferent  terminals,  such as PACAP. The well-known inhibitory effect  of
opioids on the release of these transmitters works both ways, and PACAP, and also related
mediators, are likely to exert an inhibitory effect on opioid release. It has been verified that
PACAP-ir  terminals  synapse  onto  Dyn-expressing  neurons  [98].  PACAP can  therefore  be
suggested to be a regulator of the opioidergic antinociceptive system, which is mostly silent
under normal conditions.
The central nucleus of the amygdala, an important junction of nociception-related pathways
(besides   stress   and   emotion),   has   been   found   to   display   considerable   PACAP
immunoreactivity  in  its  lateral  capsular  division,  partially  colocalized  with  CGRP.  The
immunoreactive regions represent sensory projections from the lateral parabrachial nucleus
along the  spino-parabrachioamygdaloid  tract.  Intra-amygdalar  infusion of  PACAP led to  a
marked pronociceptive effect (besides increased anxiety and weight loss), demonstrated by
decreased thermo- and mechanonociceptive thresholds in rats. Importantly, administration of
the PAC
1
-specific agonist maxadilan yielded similar results, implicating the involvement of
the PAC
1  
receptor in this phenomenon. In view of these results, PACAP signalling was
suggested to be a link between chronic pain and negative behavioural changes (anxiety and
depression) [99] (Table 1, Fig. 2).
Knockout studies: a PACAP deficiency diminishes nociceptive behaviour
Interestingly,   PACAP   gene-deficient   mice   demonstrate   an   absence   of   mechanical 
hyperalgesia in inflammatory (carrageenan) and neuropathic (L5 spinal nerve transection and 
partial  sciatic  nerve  ligation)  pain  models  [100-102],  while  their  normal  nocifensive 
behaviour remains unaffected. Despite the significantly reduced hyperalgesia observed in 
PACAP knockouts in the chronic mononeuropathy model, the early marker of neuronal 
activation, c-fos in the PAG and the somatosensory cortex was markedly higher, suggesting a 
potential inhibitory action of PACAP on inhibitory neuronal circuits [101]. The NADPH- 
dependent nitric oxide (NO) synthase (NOS) activity was increased in the superficial layer of 
the spinal dorsal horn in the wild-type, but not in PACAP gene-deficient neuropathic mice. I.t. 
NMDA injection-induced mechanical hyperalgesia was also absent in PACAP knockouts, but 
could be restored by exogenous PACAP administration [100]. A PACAP deficiency reduced 
nocifensive behaviour in both the acute (0-5 min) and the late phase (20-45 min) of the
formalin test, and additionally the number of abdominal contractions in the acetic acid-evoked
acute visceral nociception model. Intraplantar RTX-induced mechanical hyperalgesia (which
incorporates both  central  and  peripheral  components)  was  diminished,  whereas  thermal
hyperalgesia (a  primarily peripheral process) was elevated in PACAP gene-deficient mice
[101].  PACAP-deleted  animals  also  exhibited  diminished  mechanical  hyperalgesia  and
overall inflammation severity in the K/BxN model of immune-mediated chronic arthritis
[103] (Table 1).
Role of the PAC
1 
receptor in nociceptive transmission
I.t.  administration  of  the  PAC
1 
receptor  antagonist  PACAP6-38  decreased  the  flinching
behaviour   of   the   rat   following   intraplantar   formalin   injection,   diminished   the
mechanociception in the spinal nerve ligation-evoked neuropathy model and also ameliorated
the thermal  hyperalgesia  in  the  carrageenan-induced  paw inflammation  model  in  a  dose-
dependent  manner,  without  any  detrimental  effect  on  motor  coordination.  These  results
suggest that central (spinal cord) activation of PAC
1 
is pronociceptive [104]. It is important to
note,  however,  that  the  antagonistic  nature  of  PACAP6-38  has  been  questioned,  as  in
numerous tissues/cell types it has been found to exert agonistic actions similar to those of
PACAP-38  [105].  Others  have  verified  the  i.t.  antinociceptive  effect  of  PACAP6-38,  and
observed that spinal κ-opioid antagonism by nor-binaltorphimine administration abolished
this effect [98]. PAC
1  
antagonism by PACAP6-38 is therefore likely to trigger spinal Dyn
release,  resulting  in  κ-opioid  receptor  activation  and  hence  antinociception.  Earlier
investigations on PAC
1  
gene-deficent mice also revealed a significant reduction of writhing
behaviour in the late phase of the formalin test, but their thermo- and mechanonociceptive
thresholds were unaltered under normal conditions [106; 107]. The lack of difference in the
tail  pressure,  tail  flick  and  hot  plate  tests  supported  these  findings,  as  PAC
1 
signalling
apparently did not contribute to acute somatic pain perception at the periphery. It was further
observed that, while there was a dramatic decrease in the abdominal writhing test in another
PAC
1 
knockout strain, forebrain-specific PAC
1
-deleted (PAC
1
CaMKCre2) mice did not display a
similar reduction of acute visceral nocifensive reactions (PAC
1   
deletion affected the
hippocampus, the cortical regions of the forebrain, and the olfactory bulbs in these mice)
[107] (Table 1).
The currently available results well substantiate the PAC
1  
receptor as a mediator of the 
pronociceptive effects in the CNS, whereas its role in peripheral nociceptive transmission 
remains poorly understood.
The role of the VPAC
1 
and VPAC
2 
receptors in nociceptive transmission
As both PACAP and VIP are potent agonists at these receptors, elucidation of their individual
effects  and  importance  remains  a  challenge.  To  exclude  interferences  caused  by  PAC
1
-
mediated effects, most of the results relating to the role of VPAC receptors in nociception
were obtained by using VIP and its antagonists.
Early studies with receptor-specific antagonists revealed that, in the chronic constriction nerve
injury (CCI)-evoked neuropathy model, VPAC
1
,  VPAC
2 
and PAC
1 
receptor antagonism
inhibited the activity of the dorsal horn neurons induced by the Transient Potential Ankyrin
receptor  1  agonist  mustard oil,  but  did not  influence the  effect  of  mechanical  stimulation
(brush). Furthermore, the neuronal activity evoked by cold stimuli was ameliorated by VPAC
1
and PAC
1
,  but not VPAC
2 
receptor antagonists. Experimental CCI-induced neuropathy
decreased VPAC
1  
and increased VPAC
2  
mRNA expression in the ipsilateral spinal dorsal
horn (laminae III-IV), but in contrast, the PAC
1  
receptor expression remained unchanged
[108]. Administration of VIP into the basolateral amygdala diminished the heat-induced tail
flick reflex in anaesthetized rats, presumably by exciting neurons originating in the amygdala
and synapsing on inhibitory cells of the PAG [109]. Spinal VPAC
2 
receptor activation in the
rat neuropathy model induced a downstream activation of p38 and p42/44 mitogen-activated
protein (MAP) kinases in spinal glial cells by phosphorylation.  Antagonism of these MAP
kinases resulted in diminished sensitization of the dorsal horn neurons following a mustard oil
challenge, and also reduced thermal and mechanical reflex sensitization. I.t. administration of
a VPAC
2
, but not a VPAC
1 
or PAC
1 
receptor antagonist was able to diminish the sensitization
to thermal and mechanical stimulation in neuropathic rats. In contrast, i.t. administration of a
VPAC
2   
receptor agonist increased thermal hyperalgesia, which could be blocked by
coadministration of a p38 inhibitor [110]. The VPAC
1
/
2 
receptor antagonist VIP6-28 inhibited
peripheral sensitization by VIP upon topical administration around the osteoarthritic joints of
rats [111]. These results suggest a similar effect of PACAP to that of VIP acting at the common
VPAC  receptors,  which  have  been  implicated  as  potential  targets  in  the  treatment  of
neuropathic pain [112].
Activation of these receptors exerts a mostly pronociceptive effect in the CNS, while at the 
periphery their role appears to be more ambiguous. Human studies have demonstrated that 
both PACAP-38 and VIP generate a painful neurogenic inflammatory reaction upon intradermal 
administration, which can be attributed to the VPAC receptors [44]. In mouse pain models, 
where the peripheral administration of PACAP-38 resulted in diminished nociception, 
coadministered VPAC
1
/
2  
antagonists abolished this effect [84], suggesting that
these receptors also contribute to antinociceptive signalling at the periphery. However, the
algesic effect of PACAP is likely to be caused by a local mast cell degranulating potential of
the peptide, unrelated to its action on the nociceptors. VPAC
2
, but not VPAC
1
, is present on
human mast cells [113], and both VIP and PACAP potently induce their degranulation [72;
114].  This  is  supported  by the  finding  that  topical  PACAP-38-induced  dermal  oedema is
completely  abolished  in  mast  cell-deficient  mice  [114].  These  results  suggest  that  the
observed algesia is likely to be caused by VPAC
2
-mediated  mast cell degranulation and
secondary neurogenic inflammation. Moreover, the reported pain-inducing effect of PACAP-
38 is extremely short-lasting (it ceased within 2 min) [44], and this transient pronociceptive
impact of the peptide therefore does not contradict the observed permanent analgesic effect of
peripherally  administered  PACAP-38  (presumably  acting  on  sensory  afferent  endings)  in
murine models (Table 1).
PACAP and migraine
Preclinical  and human data  point  to  the involvement  of PACAP in the pathophysiological
mechanisms of migraine.
Nitroglycerol (NTG) is a NO donor which causes an immediate and a delayed migraine-like
attack  in  migraine  patients  without  aura [115].  It  is  therefore  a  useful  tool  for  chemical
activation of the TS in animal models that mimic the symptoms of migraine. NTG-evoked
pathophysiological  changes  in  the  TS,  such  as  light-aversive  behaviour,  meningeal
vasodilatation  and  c-fos  activation  in  the  TRIG  and  TNC,  were  significantly  reduced  in
PACAP-deficient  mice.  Moreover, the systemic administration of PACAP-38 elicited light
aversion, similarly to that of NTG in wild-type mice, but not in PACAP-deficient ones [23]
showing   that   PACAP   plays   a   crucial   role   in   both   the   vascular   and   neuronal
pathophysiological mechanisms of migraine.
Another model of the migraine attack is the electrical stimulation of the TRIG [116; 117].
Both chemical (NTG) and electrical (square pulses) stimulation of the TRIG in rats resulted in
significantly elevated concentrations of PACAP-27 and -38 in the TNC. The plasma PACAP-
38 immunoreactivity increased following electrical stimulation [22], suggesting that these 
peptides are closely related to TS activation and the nociceptive transmission in the TNC. 
Intravenously administered PACAP-38 induces headache in healthy volunteers and delayed 
migraine-like attacks in patients with migraine without aura [18], similarly to the action of 
NTG in migraineurs [115; 118]. A decreased mean blood flow velocity in the middle cerebral 
artery  and  an  increased  diameter  of  the  superficial  temporal  artery  were  observed  [18].
Further, pronounced dilation of the extracranial, but not the intracranial arteries was revealed
[19]. Recent findings have revealed that a PACAP-38 infusion causes dilation of the middle
meningeal  artery  in  rats,  which  is  diminished  in  mast  cell-depleted  and  antihistamine-
pretreated rats [119]. The observed vasodilating effects are therefore likely to be indirect and
mediated by the PACAP-38-induced histamine release from the mast cells [119]. In another
human study, significantly lower interictal plasma PACAP-38 immunoreactivity was detected
in  migraineurs  as  compared  with  the  healthy  control  group.  In  contrast,  elevated  plasma
PACAP-38 and CGRP levels  were  measured  in  the  ictal  phase  relative  to  the  attack-free
period. A negative correlation was detected between the PACAP-38 plasma concentration in
the  attack-free  period  and the  disease  duration.  The plasma changes  were independent  of
various  disease  conditions  [21].  These  results  suggest  a  correlation  between  the
attack/headache-free period and the plasma PACAP-38 levels.
Presumably,  PACAP  can  be  released  from  the  peripheral  and  central  terminals  of  the
pseudounipolar primary sensory neurons of the TRIG in response to stimulation. It acts
locally, but also enters the systemic circulation. Activation of PAC
1 
and VPAC
2 
receptors can
elicit vasodilation in the meningeal vessels; the VPAC
1 
receptor is important in the vascular
responses of the cerebellar arteries [70]. The PAC
1 
receptor is also involved in the activation
of  the  second-order  sensory  neurons  [23],  which  appears  consistent  with  previous
interpretations implicating PAC
1  
receptors in migraine [18; 120]. This is in agreement with
the results that intradermal injections of PACAP-38 or VIP elicit mild, short-lasting cutaneous
pain and increased skin blood flow,  flare  and wheal  in  healthy volunteers,  supporting the
concept that primarily the VPAC, and not the PAC
1 
receptors mediate these alterations. There
is  experimental  evidence  that  PACAP  induces  neurogenic  inflammation,  mast  cell
degranulation, neuronal activation and sensitization [18; 121]. The participation of PACAP in
the processes of migraine may be confirmed by the finding that PACAP-induced dilation of
the middle meningeal artery and headache pain are attenuated by the serotonin 5-HT1B/D
receptor agonist sumatriptan [20]. Overall, there is strong clinical and experimental evidence
of an  important  mediator role  of PACAP in  many  components  of migraine through  the
initiation,  promotion  of  the  development  and/or  aggravation  of  the  severity  of  headache
attacks (Fig. 3).
The relevance and potential future therapeutic applications of PACAP
The broad range of clinical and experimental evidence described above clearly reveals that
PACAP is an important mediator of pain processing and a key player in migraine headache.
Since most of the effects of PACAP on nociception are different from those of VIP [19; 122],
it may be proposed that the main actions in pain are mediated via the specific PAC1 receptor.
However, due to the lack of availability of stable, receptor-selective non-peptide agonists and
antagonists  with  a  good  blood-brain-barrier  (BBB)  penetration  ability,  its  target(s)  and
signalling mechanisms have not been elucidated. Several data show that a fragment of the full
peptide,  PACAP6-38,  acting  as  a  potent  PAC
1
/VPAC
2  
antagonist  in  a  variety  of  model
systems [123-128], behaves as an agonist on rat primary TRIG cultures, similarly to PACAP
itself [129], and on the peripheral terminals of primary sensory neurons both in vitro [105;
130] and in vivo [131]. It can be therefore suggested that primary sensory neurons do not
express the same PAC
1 
receptor as previously cloned, but either a PAC
1
-related receptor or a
different  PAC1  splice  variant. Unravelling  the  molecular  pathways  and  deciphering  the
downstream mechanisms could open up promising perspectives for the development of novel
analgesic drugs.
Maxadilan, a 61 AA PAC
1  
receptor-specific peptide agonist, is already available; deletion
between the 25 and 41 amino acids yielded the specific PAC
1  
receptor antagonist Maxa-65
[132].    As  concerns  our  current  understanding  of  the  role  of  PACAP  in  migraine,  and
available mechanistic insights, the immediate aim can be defined as the development of a
non-peptide specific PAC
1 
receptor antagonist capable of efficient BBB penetration, thereby
of future  clinical  use in  the  treatment  of  migraine-induced headache,  and potentially in  a
plethora of other pain conditions too.
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BBB: blood brain barrier
CCI: chronic constriction injury 
CGRP: calcitonin gene-related peptide
CNS: central nervous system
CSD: cortical spreading depression
DRG: dorsal root ganglion
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i.t.: intrathecal
ir: immunoreactive
LC: locus coeruleus
MAP: mitogen-activated kinase
NGF: nerve growth factor
NO: nitric oxide
NOS: nitric oxide synthase
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1
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PAG: periaqueductal grey matter 
PNS: peripheral nervous system 
RTX: resiniferatoxin
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TNC: trigeminal nucleus caudalis
TRIG: trigeminal ganglion
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VPAC
1
: VIP1 or PACAP type II receptor 
VPAC
2
: VIP2 or PACAP type III receptor
Figures
Figure 1.  Scheme of the PACAP-related components in the trigeminal system (Modified ref.
14).
Abbreviations:
C
2
:  cervical  2  segments  of  spinal  cord;  DRG:  dorsal  root  ganglion;  DRN:  dorsal  raphe
nucleus;  NRM:  nucleus  raphe  magnus;  LC:  locus  coeruleus;  PAG:  periaqueductal  grey
matter; TNC: trigeminal nucleus caudalis; TRIG: trigeminal ganglion; +: presence
Figure 2. Effects of PACAP in nociceptive transmission
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Figure 3. Putative mechanism of PACAP in migraine headache
Abbreviations:
PACAP:   pituitary   adenylate   cyclase-activating   polypeptide;   TNC:   trigeminal   nucleus 
caudalis; TRIG: trigeminal ganglion
Tables
Table 1. The effects of PACAP on nociception/pain perception.
Localization Effect on 
nociception
Model(s) Species
studied
Readout Receptor(s)
implicated
Ref.
i.pl./s.c. 
PACAP-38
↓ (acute
models)
-
(neuropathy
model)
i.pl. carrageenan,
i.pl. formalin,
i.p. acetic acid,
partial sciatic nerve
ligation
mouse mechanical and
thermal nociceptive
threshold,
writhing test
VPAC
1
/
2
[84]
i.d. PACAP-
38
↑ study on healthy
volunteers
human visual analogue scale VPAC
1
/
2 
on 
mast cells
[44]
i.t. PACAP-
27/-38 (high
dose)
↓ i.pl. formalin rat flinching behaviour n.a. [92]
i.t. PACAP-27 ↓ i.pl. formalin rat flinching behaviour n.a. [93]
i.t. PACAP-38 ↑ thermonociception,
spontaneous pain
behaviour
rat tail-flick latency,
behavioural
observation
n.a. [95]
i.t. PACAP-38 ↓(early
phase)
↑(late 
phase)
thermonociception,
spontaneous pain
behaviour
mouse tail-flick latency,
behavioural
observation
n.a. [96]
i.t. PACAP-38 ↑ thermonociception,
i.t. NMDA,
i.pl. formalin
mouse paw-withdrawal
latency, behavioural
observation
n.a. [97]
intraamygdalar
PACAP-38
↑ thermo- and 
mechanonoception
rat Paw- withdrawal
threshold
PAC
1
[99]
global PACAP
knockout
↓ spinal nerve
transection,
i.pl. carrageenan,
i.t. NMDA
mouse mechanical and
thermal  nociceptive
threshold
n.a. [100]
global PACAP
knockout
↓ i.pl. formalin,
intraplantar
resiniferatoxin
partial sciatic nerve
ligation,
i.p. acetic acid
behavioural
observation, mechano-
and thermonociceptive
threshold,
abdominal writhing
n.a. [101]
global PACAP
knockout
↓ partial sciatic nerve
ligation
mouse mechanonociceptive
threshold
n.a. [102]
global PACAP
knockout
↓ K/BxN serum- 
transfer arthritis
mouse mechanonociceptive
threshold
n.a. [103]
i.t. PACAP
antagonist
(6-38)
↓ i.pl. formalin, spinal
nerve ligation,
intraplantar
carrageenan
monoiodo-acetate-
induced
osteoarthritis
rat flinching behaviour,
mechano- and
thermonociceptive
threshold,
hind limb weight-
bearing difference
PAC
1
[104]
i.t. PACAP
antagonist
(6-38)
↓ i.pl. formalin rat behavioural
observation
PAC
1
[98]
global PAC
1knockout
↓ (only in
the formalin
test)
i.pl. formalin,
thermo- and
mechanonociception
mouse behavioural
observation,
mechano- and
thermonociceptive
threshold
PAC
1
[106]
global and
forebrain-
specific PAC
1
knockout
↓ in global
knockouts
(only
visceral
nociception)
thermo- and
mechanonociception,
i.p. acetic acid
mouse mechano- and
thermonociceptive
threshold,
abdominal writhing
PAC
1
[107]
Abbreviations:
i.d. = intradermally, i.t. = intrathecally, i.p. = intraperitoneally, i.pl. = intraplantarly, 
s.c. = subcutaneously, n.a. = not available
Table 2. Distribution of PACAP and its receptors in the trigeminovascular system
PACAP PAC1 VPAC1 VPAC2 References
Dura mater + + + + [70; 71]
Cortex + + + + [2; 31]
Raphe nuclei + + no data no data [2; 31]
LC + + no data no data [2; 31; 45]
PAG + + no data no data [2; 31; 45]
TNC + + + no data [2; 31; 32; 68]
TRIG + + + + [2; 31; 73-75]
Abbreviations:
C
2
:  cervical  2  segments  of  spinal  cord;  DRG:  dorsal  root  ganglion;  DRN:  dorsal  raphe
nucleus;  NRM:  nucleus  raphe  magnus;  LC:  locus  coeruleus;  PAG:  periaqueductal  grey
matter; TNC: trigeminal nucleus caudalis; TRIG: trigeminal ganglion; +: presence
Figure legends
Figure 1.
PACAP and its receptors are expressed in the different levels of the trigeminovascular system.
Figure 2.
The     divergent     effects     of     PACAP     on     nociceptive     signalling     and     related
functions in the central nervous system and on the periphery. 1. Sensory nerve terminal, 2.
Dorsal root ganglion, 3. Spinal dorsal horn, 4. Amygdala
Figure 3.
The activation of TRIG may lead to the release of PACAP-38 from the peripheral and central
terminals of the sensory nerves. Meningeal vasodilation, mast cell degranulation and neuronal
activation  and  sensitization  in  the  TNC  may  be  consequences  of  the  extra  neuropeptide
release. Clinically it may explain the throbbing headache, which is aggravated by physical
activity, and also the cranial and extracranial cutaneous allodynia during migraine attack.
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